PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Altimmune, Inc. (ALT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS02155H2004
CUSIP02155H200
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$445.97M
EPS (TTM)-$1.60
PE Ratio33.50
Total Revenue (TTM)$410.00K
Gross Profit (TTM)-$33.23M
EBITDA (TTM)-$84.60M
Year Range$2.09 - $14.84
Target Price$20.57
Short %32.78%
Short Ratio7.47

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Altimmune, Inc.

Popular comparisons: ALT vs. TQQQ, ALT vs. lly, ALT vs. VOO, ALT vs. XLK, ALT vs. BLNK, ALT vs. FDVV

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Altimmune, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%400.00%2024FebruaryMarchAprilMayJune
-99.72%
359.36%
ALT (Altimmune, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Altimmune, Inc. had a return of -47.38% year-to-date (YTD) and 48.00% in the last 12 months. Over the past 10 years, Altimmune, Inc. had an annualized return of -35.02%, while the S&P 500 had an annualized return of 10.85%, indicating that Altimmune, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-47.38%15.04%
1 month-26.09%3.47%
6 months-28.67%15.07%
1 year48.00%24.43%
5 years (annualized)20.56%13.22%
10 years (annualized)-35.02%10.85%

Monthly Returns

The table below presents the monthly returns of ALT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-16.09%28.18%-15.87%-35.66%14.66%-47.38%
2023-17.08%-7.70%-66.48%19.67%-20.00%-12.62%-6.23%-23.56%2.77%-7.31%31.12%256.01%-31.61%
2022-11.90%-8.18%-17.81%-25.78%11.95%131.23%2.65%83.85%-42.16%-1.80%-20.65%65.33%79.59%
202126.60%11.62%-11.36%2.41%-12.58%-22.13%-7.92%65.27%-24.55%-4.51%-2.87%-12.68%-18.79%
2020-8.99%115.12%-13.24%-4.98%204.26%15.41%148.18%-36.53%-21.75%-13.26%6.81%-7.77%496.83%
201954.85%-15.67%7.81%-1.38%-15.03%-2.06%0.84%-12.08%-7.58%-2.05%-4.71%3.85%-8.25%
2018-9.05%-12.71%-26.58%-37.49%-15.86%-27.06%-25.15%-3.93%-54.17%-13.41%-5.77%-42.62%-96.55%
2017-4.62%-70.88%-9.83%-10.44%-41.52%-24.71%-21.25%0.00%-7.94%3.45%-24.58%9.94%-93.86%
2016-17.37%8.28%11.18%25.93%-5.88%8.93%4.92%1.56%11.54%-5.17%10.91%6.56%71.05%
2015-8.84%1.82%-2.98%1.23%3.64%5.26%-6.11%-14.20%-8.28%26.32%4.76%7.95%4.97%
20142.69%-2.09%-2.14%-24.59%18.84%-14.02%-7.80%76.15%-22.27%-1.12%-3.41%6.47%-2.69%
201327.68%-9.09%30.77%-7.06%12.66%-10.67%11.32%20.90%-1.87%-2.38%-8.78%-0.53%66.07%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALT is 68, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of ALT is 6868
ALT (Altimmune, Inc.)
The Sharpe Ratio Rank of ALT is 6464Sharpe Ratio Rank
The Sortino Ratio Rank of ALT is 7373Sortino Ratio Rank
The Omega Ratio Rank of ALT is 6969Omega Ratio Rank
The Calmar Ratio Rank of ALT is 6969Calmar Ratio Rank
The Martin Ratio Rank of ALT is 6464Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Altimmune, Inc. (ALT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ALT
Sharpe ratio
The chart of Sharpe ratio for ALT, currently valued at 0.43, compared to the broader market-2.00-1.000.001.002.003.000.43
Sortino ratio
The chart of Sortino ratio for ALT, currently valued at 1.47, compared to the broader market-4.00-2.000.002.004.001.47
Omega ratio
The chart of Omega ratio for ALT, currently valued at 1.17, compared to the broader market0.501.001.502.001.17
Calmar ratio
The chart of Calmar ratio for ALT, currently valued at 0.45, compared to the broader market0.002.004.006.000.45
Martin ratio
The chart of Martin ratio for ALT, currently valued at 1.34, compared to the broader market0.0010.0020.001.34
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.17, compared to the broader market-2.00-1.000.001.002.003.002.17
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.07, compared to the broader market-4.00-2.000.002.004.003.07
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.501.001.502.001.38
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.73, compared to the broader market0.002.004.006.001.73
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.12, compared to the broader market0.0010.0020.008.12

Sharpe Ratio

The current Altimmune, Inc. Sharpe ratio is 0.43. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Altimmune, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.002024FebruaryMarchAprilMayJune
0.43
2.10
ALT (Altimmune, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

Altimmune, Inc. granted a 0.00% dividend yield in the last twelve months. The annual payout for that period amounted to $0.00 per share.


PeriodTTM2023202220212020201920182017
Dividend$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.91

Dividend yield

0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.87%

Monthly Dividends

The table displays the monthly dividend distributions for Altimmune, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2022$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2021$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2020$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2019$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2018$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2017$2.91$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.91

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%2024FebruaryMarchAprilMayJune
-99.78%
0
ALT (Altimmune, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Altimmune, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Altimmune, Inc. was 99.94%, occurring on Nov 19, 2019. The portfolio has not yet recovered.

The current Altimmune, Inc. drawdown is 99.78%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.94%Mar 15, 20063409Nov 19, 2019
-4.98%Feb 28, 20065Mar 6, 20063Mar 9, 20068
-2.7%Oct 31, 20056Nov 7, 200532Dec 23, 200538
-2.25%Feb 7, 20067Feb 15, 20065Feb 23, 200612
-2.25%Jan 3, 20064Jan 6, 200616Jan 31, 200620

Volatility

Volatility Chart

The current Altimmune, Inc. volatility is 19.85%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%2024FebruaryMarchAprilMayJune
19.85%
2.33%
ALT (Altimmune, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Altimmune, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items